Physician profile
John Houston
NPI 1841201274
$1,618.05
in general payments reported to CMS, 2019-2025
27 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $174 · 2021: $466 · 2022: $281 · 2023: $165 · 2024: $159 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $329.15 | 2021-2023 | |
| Novo Nordisk INC | $241.82 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $119.50 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $79.87 | 2022-2025 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $70.92 | 2024-2025 | |
| Indivior INC. | $70.53 | 2020-2025 | Sublocade |
| Merck Sharp & Dohme LLC | $68.34 | 2019-2022 | |
| Abbott Laboratories | $60.61 | 2021-2022 | |
| Pfizer INC. | $59.56 | 2021 | |
| Lilly USA, LLC | $54.39 | 2020-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $52.90 | 2020-2021 | |
| Almatica Pharma LLC | $50.69 | 2024 | Loreev Xr |
| Allergan, INC. | $43.88 | 2020 | |
| Xeris Pharmaceuticals, INC. | $41.80 | 2021-2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.82 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.79 | 2024 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $29.92 | 2021 | |
| Shire North American Group INC | $28.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.31 | 2021 | |
| Eisai INC. | $18.22 | 2021 | |
| Astellas Pharma US INC | $17.05 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.98 | 2024 | Zoryve |
| Esperion Therapeutics, INC. | $14.89 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.59 | 2022 | |
| Daiichi Sankyo INC. | $14.39 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.00 | 2022 | |
| Boston Scientific Corporation | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Houston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.